https://doi.org/10.4081/reumatismo.2023.1571
Diagnosis and treatment of interstitial lung disease related to systemic autoimmune myopathies: a narrative review
Submitted: 21 February 2023
Accepted: 5 April 2023
Published: 8 May 2023
Accepted: 5 April 2023
Abstract Views: 1607
PDF: 885
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Systemic autoimmune myopathies (SAMs) are rare diseases that lead to muscle inflammation and may be associated with a variety of systemic manifestations. Although there is great heterogeneity in the spectrum of extra-muscular involvement in SAMs, interstitial lung disease (ILD) is the most frequent lung manifestation. SAM-related ILD (SAM-ILD) presents significant variations according to geographic location and temporal trends and is associated with increased morbidity and mortality. Several myositis autoantibodies have been discovered over the last decades, including antibodies targeting aminoacyl-tRNA synthetase enzymes, which are associated with a variable risk of developing ILD and a myriad of other clinical features. In this review, the most relevant topics regarding clinical manifestations, risk factors, diagnostic tests, autoantibodies, treatment, and prognosis of SAM-ILD are highlighted. We searched PubMed for relevant articles published in English, Portuguese, or Spanish from January 2002 to September 2022. The most common SAM-ILD patterns are nonspecific interstitial pneumonia and organizing pneumonia. The combination of clinical, functional, laboratory, and tomographic features is usually sufficient for diagnostic confirmation, without the need for additional invasive methods. Glucocorticoids remain the first-line treatment for SAM-ILD, although other traditional immunosuppressants, such as azathioprine, mycophenolate, and cyclophosphamide have demonstrated some efficacy and, therefore, have an important role as steroid-sparing agents.
Sun KY, Fan Y, Wang YX, Zhong YJ, Wang GF. Prevalence of interstitial lung disease in polymyositis and dermatomyositis: a meta-analysis from 2000 to 2020. Semin Arthritis Rheum. 2021; 51: 175-91.
DOI: https://doi.org/10.1016/j.semarthrit.2020.11.009
Lega JC, Reynaud Q, Belot A, Fabien N, Durieu I, Cottin V. Idiopathic inflammatory myopathies and the lung. Eur Respir Rev. 2015; 24: 216-38.
DOI: https://doi.org/10.1183/16000617.00002015
Cottin V, Thivolet-Béjui F, Reynaud-Gaubert M, Cadranel J, Delaval P, Ternamian PJ, et al. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis, and polymyositis. Eur Respir J. 2003; 22: 245-50.
DOI: https://doi.org/10.1183/09031936.03.00026703
Saketkoo LA, Ascherman DP, Cottin V, Christopher-Stine L, Danoff SK, Oddis CV. Interstitial lung disease in idiopathic inflammatory myopathy. Curr Rheumatol Rev. 2010; 6: 108-19.
DOI: https://doi.org/10.2174/157339710791330740
Egashira R. High-resolution CT findings of myositis-related interstitial lung disease. Medicina (Kaunas). 2021; 57: 692.
DOI: https://doi.org/10.3390/medicina57070692
Waseda Y. Myositis-related interstitial lung disease: a respiratory physician’s point of view. Medicina (Kaunas). 2021; 57: 599.
DOI: https://doi.org/10.3390/medicina57060599
Fujisawa T. Management of myositis-associated interstitial lung disease. Medicina (Kaunas). 2021; 57: 347.
DOI: https://doi.org/10.3390/medicina57040347
Marie I, Josse S, Decaux O, Dominique S, Diot E, Landron C, et al. Comparison of long-term outcome between anti-Jo1 and anti-PL7/PL12 positive patients with anti-synthetase syndrome. Autoimmun Rev. 2012; 11: 739-7.
DOI: https://doi.org/10.1016/j.autrev.2012.01.006
Kim SH, Park IN. Acute respiratory distress syndrome as the initial clinical manifestation of an antisynthetase syndrome. Tuberc Respir Dis. 2016; 79: 188-92.
DOI: https://doi.org/10.4046/trd.2016.79.3.188
Baccaro ACCD, Behrens Pinto GL, Carboni RCS, Shinjo SK. The clinical manifestations at the onset of antisynthetase syndrome: a chameleon with multiple faces. Reumatismo. 2020; 72: 86-92.
DOI: https://doi.org/10.4081/reumatismo.2020.1275
Long K, Danoff SK. Interstitial lung disease in polymyositis and dermatomyositis. Clin Chest Med. 2019; 40: 561-72.
DOI: https://doi.org/10.1016/j.ccm.2019.05.004
Johnson C, Pinal-Fernandez I, Parikh R, Paik J, Albayda J, Mammen AL, et al. Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease. Lung. 2016; 194: 733-7.
DOI: https://doi.org/10.1007/s00408-016-9896-x
Bai Z, Shen G, Dong L. Analysis of risk factors of interstitial lung disease and mortality rates in Chinese patients with idiopathic inflammatory myopathy. Int J Rheum Dis. 2021; 24: 815-27.
DOI: https://doi.org/10.1111/1756-185X.14128
Chua F, Higton AM, Colebatch AN, O’Reilly K, Grubnic S, Vlahos I, et al. Idiopathic inflammatory myositis-associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort. Rheumatology (Oxford). 2012; 51: 1870-6.
DOI: https://doi.org/10.1093/rheumatology/kes167
ZuoY, Ye L, Chen F, ShenY, Lu X, Wang G, et al. Different multivariable risk factors for rapid progressive interstitial lung disease in anti-MDA5 positive dermatomyositis and anti-synthetase syndrome. Front Immunol. 2022; 13: 845988.
DOI: https://doi.org/10.3389/fimmu.2022.845988
Zhang L, Wu G, Gao D, Liu G, Pan L, Ni L, et al. Factors associated with interstitial lung disease in patients with polymyositis and dermatomyositis: a systematic review and meta-analysis. PLoS One. 2016; 11: e01.
DOI: https://doi.org/10.1371/journal.pone.0155381
Barba T, Mainbourg S, Nasser M, Lega JC, Cottin V. Lung diseases in inflammatory myopathies. Semin Respir Crit Care Med. 2019; 40: 255-70.
DOI: https://doi.org/10.1055/s-0039-1685187
Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum. 2011; 63: 3439-47.
DOI: https://doi.org/10.1002/art.30513
Zamora AC, Hoskote SS, Abascal-Bolado B, White D, Cox CW, Ryu JH, et al. Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome. Respir Med. 2016; 118: 39-45.
DOI: https://doi.org/10.1016/j.rmed.2016.07.009
Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official american thoracic society/european respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013; 188: 733-48.
DOI: https://doi.org/10.1164/rccm.201308-1483ST
Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, et al. An official european respiratory society/american thoracic society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015; 46: 976-87.
DOI: https://doi.org/10.1183/13993003.00150-2015
Baque-Juston M, Pellegrin A, Leroy S, Marquette CH, Padovani B. Organizing pneumonia: what is it? A conceptual approach and pictorial review. Diagn Interv Imaging. 2014; 95: 771-7.
DOI: https://doi.org/10.1016/j.diii.2014.01.004
King TE Jr, Lee JS. Cryptogenic organizing pneumonia. N Engl J Med. 2022; 386: 1058-69.
DOI: https://doi.org/10.1056/NEJMra2116777
Fischer A, Swigris JJ, du Bois RM, Lynch DA, Downey GP, Cosgrove GP, et al. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir Med. 2019; 103: 1719-24.
DOI: https://doi.org/10.1016/j.rmed.2009.05.001
Hallowell RW, Paik JJ. Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management. Clin Exp Rheumatol. 2022; 40: 373-83.
DOI: https://doi.org/10.55563/clinexprheumatol/brvl1v
Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/ JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183: 788-824.
DOI: https://doi.org/10.1164/rccm.2009-040GL
Chung JH, Cox CW, Montner SM, Adegunsoye A, Oldham JM, Husain AN, et al. CT features of the usual interstitial pneumonia pattern: differentiating connective tissue disease-associated interstitial lung disease from idiopathic pulmonary fibrosis. AJR Am J Roentgenol. 2018; 210: 307-13.
DOI: https://doi.org/10.2214/AJR.17.18384
Wuyts WA, Cavazza A, Rossi G, Bonella F, Sverzellati N, Spagnolo P. Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic? Eur Respir Rev. 2014; 23: 308-19.
DOI: https://doi.org/10.1183/09059180.00004914
Jablonski R, Bhorade S, Strek ME, Dematte J. Recognition and management of myositis-associated rapidly progressive interstitial lung disease. Chest. 2020; 158: 252-63.
DOI: https://doi.org/10.1016/j.chest.2020.01.033
Zompatori M, Ciccarese F, Fasano L. Overview of current lung imaging in acute respiratory distress syndrome. Eur Respir Rev. 2014; 23: 519-30.
DOI: https://doi.org/10.1183/09059180.00001314
Li C, Liang M, Jiang H, Zhao J, Wu C, Wang Q, et al. The long-term prognosis of pneumomediastinum associated with dermatomyositis: a two-centre retrospective cohort study. Rheumatology (Oxford). 2021; 60: 2288-95.
DOI: https://doi.org/10.1093/rheumatology/keaa582
American thoracic society/european respiratory society. ATS/ ERS statement on respiratory muscle testing. Am J Respir Crit Care Med. 2012; 166: 518-624.
DOI: https://doi.org/10.1164/rccm.166.4.518
Ciancio N, Pavone M, Torrisi SE, Vancheri A, Sambataro D, Palmucci S, et al. Contribution of pulmonary function tests (PFTs) to the diagnosis and follow up of connective tissue diseases. Multidiscip Respir Med. 2019; 14: 17.
DOI: https://doi.org/10.4081/mrm.2019.17
HeL,GeY,LiS,HuangK,LiuX,ChenF,et al. Clinical role of bronchoalveolar lavage in dermatomyositis-associated interstitial lung disease. Rheumatology (Oxford). 2022; 61: 345-54.
DOI: https://doi.org/10.1093/rheumatology/keab586
Souza FHC. Autoanticorpos em miopatias autoimunes. Rev Paul Reumatol. 2017; 16: 12-6.
DOI: https://doi.org/10.46833/reumatologiasp.2017.16.4.12-16
Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140).
J Am Acad Dermatol. 2011; 65: 25-34.
McPherson M, Economidou S, Liampas A, Zis P, Parperis K. Management of MDA-5 anti-body positive clinically amyopathic dermatomyositis associated interstitial lung disease: a systematic review. Semin Arthritis Rheum.
; 53: 151959.
Gallay L, Gayed C, Hervier B. Antisynthetase syndrome pathogenesis: knowledge and uncertainties. Curr Opin Rheumatol. 2018; 30: 664-73.
DOI: https://doi.org/10.1097/BOR.0000000000000555
Xing X, Li A, Li C. Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis. Respir Med. 2020; 172: 106134.
DOI: https://doi.org/10.1016/j.rmed.2020.106134
Sabbagh S, Pinal-Fernandez I, Kishi T, Targoff IN, Miller FW, Rider LG, et al. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis. 2019; 78: 988.
DOI: https://doi.org/10.1136/annrheumdis-2018-215004
Rigolet A, Musset L, Dubourg O, Maisonobe T, Grenier P, Charuel JL, et al. Inflammatory myopathies with anti-Ku antibodies: a prognosis dependent on associated lung disease. Medicine. 2012; 91: 95-102.
DOI: https://doi.org/10.1097/MD.0b013e31824d9cec
Liang L, Zhang YM, Chen H, Ye LF, Li SS, Lu X, et al. Anti-Mi-2 antibodies characterize a distinct clinical subset of dermatomyositis with favorable prognosis. Eur J Dermatol. 2020; Online ahead of print. doi: 10.1684/ ejd.2020.3750.
Dos Passos Carvalho MIC, Shinjo SK. Frequency and clinical relevance of anti-Mi-2 autoantibody in adult Brazilian patients with dermatomyositis. Adv Rheumatol. 2019; 59: 27.
DOI: https://doi.org/10.1186/s42358-019-0071-y
Barba T, Fort R, Cottin V, Provencher S, Durieu I, Jardel S, et al. Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis. Autoimmun Rev. 2019; 18: 113-22.
DOI: https://doi.org/10.1016/j.autrev.2018.07.013
de Souza FHC, de Araújo DB, Vilela VS, Bezerra MC, Simões RS, Bernardo WM, et al. Guidelines of the Brazilian society of rheumatology for the treatment of systemic autoimmune myopathies. Adv Rheumatol. 2019; 59: 6.
DOI: https://doi.org/10.1186/s42358-019-0048-x
Jee AS, Sheehy R, Hopkins P, Corte TJ, Grainge C, Troy LK, et al. Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: a position statement from the thoracic society of Australia and New Zealand. Respirology. 2021; 26: 23-51.
DOI: https://doi.org/10.1111/resp.13977
Kondoh Y, Makino S, Ogura T, Suda T, Tomioka H, Amano H, et al. 2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. Respir Investig. 2021; 59: 709-40.
DOI: https://doi.org/10.1016/j.resinv.2021.04.011
Romero-Bueno F, Diaz Del Campo P, Trallero-Araguás E, Ruiz-Rodríguez JC, Castellvi I, Rodriguez-Nieto MJ, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum. 2020; 50: 776-90.
DOI: https://doi.org/10.1016/j.semarthrit.2020.03.007
Oldroyd AGS, Lilleker JB, Amin T, Aragon O, Bechman K, Cuthbert V, et al. British society for rheumatology guideline on management of pediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology (Oxford). 2022; 61: 1760-8.
DOI: https://doi.org/10.1093/rheumatology/keac115
Sharma N, Putman MS, Vij R, Strek ME, Dua A. Myositis-associated Interstitial lung disease: predictors of failure of conventional treatment and response to tacrolimus in a US cohort. J Rheumatol. 2017; 44: 1612-8.
DOI: https://doi.org/10.3899/jrheum.161217
Sparks JA, Dellaripa PF, Glynn RJ, Paynter NP, Xu C, Ridker PM, et al. Pulmonary adverse events in patients receiving low-dose methotrexate in the randomized, double-blind, placebo-controlled cardiovascular inflammation reduction trial. Arthritis Rheumatol. 2020; 72: 2065-71.
DOI: https://doi.org/10.1002/art.41452
Hoff LS, de Souza FHC, Miossi R, Shinjo SK. Long-term effects of early pulse methylprednisolone and intravenous immunoglobulin in patients with dermatomyositis and polymyositis. Rheumatology (Oxford). 2022; 61: 1579-88.
DOI: https://doi.org/10.1093/rheumatology/keab597
Wang DX, Shu XM, Tian XL, Chen F, Zu N, Ma L, et al. Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review. Clin Rheumatol. 2012; 31: 801-6.
DOI: https://doi.org/10.1007/s10067-012-1940-5
Olivo Pallo PA, Hoff LS, Borges IBP, Torres-Ruiz J, Cassiano-Quezada F, Granel A, et al. Characterization of patients with dermatomyositis according to anti-melanoma differentiation-associated gene-5 autoantibodies in centers from 3 Latin American countries: a cohort study. J Clin Rheumatol. 2022; 28: e444-8.
DOI: https://doi.org/10.1097/RHU.0000000000001756
. Da Silva LMB, Rathore U, Agarwal V, Gupta L, Shinjo SK. Demographic, clinical, laboratory data, prognostic, and treatment features of patients with antisynthetase syndrome: an international, two-center cohort study. Arch Rheumatol. 2022; 37: 424-34.
DOI: https://doi.org/10.46497/ArchRheumatol.2022.9108
Finnerty JP, Ponnuswamy A, Dutta P, Abdelaziz A, Kamil H. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. BMC Pulm Med. 2021; 21: 411.
DOI: https://doi.org/10.1186/s12890-021-01783-1
Matteson EL, Kelly C, Distler JHW, Hoffmann-Vold AM, Seibold JR, Mittoo S, et al. Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: subgroup analysis of the IN-BUILD trial. Arthritis Rheumatol. 2022; 74: 1039-47.
DOI: https://doi.org/10.1002/art.42075
Misse RG, Borges IBP, Dos Santos AM, Gupta L, Shinjo SK. Effect of exercise training on fatigue and pain in patients with systemic autoimmune myopathies: a systematic review. Autoimmun Rev. 2021; 20: 102897.
DOI: https://doi.org/10.1016/j.autrev.2021.102897
Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 2017; 86: 242-51.
DOI: https://doi.org/10.1097/MD.0b013e3181441a68
Gaboriau L, Davion JB, Combret S, Lebrun-Vignes B, Rocher F, Rouby F, et al. Adalimumab and myositis: a case report and review of the French and international pharmacovigilance databases. Neuromuscul Disord. 2020; 30: 915-20.
DOI: https://doi.org/10.1016/j.nmd.2020.09.026
Zengin O, Onder ME, Alkan S, Kimyon G, Hüseynova N, Demir ZH, et al. Three cases of
anti-TNF induced myositis and literature review. Rev Bras Reumatol Engl Ed. 2017; 57: 590-5.
DOI: https://doi.org/10.1016/j.rbre.2016.05.003
Labioche I, Liozon E, Weschler B, Loustaud-Ratti V, Soria P, Vidal E. Refractory polymyositis responding to infliximab: extended follow-up. Rheumatology (Oxford). 2004; 43: 531-2.
DOI: https://doi.org/10.1093/rheumatology/keh079
Rouster-Stevens KA, Pachman LM. Autoantibody to signal recognition particles in african american girls with juvenile polymyositis. J Rheumatol. 2008; 35: 927-9.
Chen D, Wang XB, Zhou Y, Zhu XC. Efficacy of infliximab in the treatment for dermatomyositis with acute interstitial pneumonia: a study of fourteen cases and literature review. Rheumatol Int. 2013; 33: 2455245-8.
DOI: https://doi.org/10.1007/s00296-012-2653-4
Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumor necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis. 2006; 65: 1233-6.
DOI: https://doi.org/10.1136/ard.2005.048744
Tjärnlund A, Tang Q, Wick C, Dastmalchi M, Mann H, Tomasová Studýnková J, et al. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Ann Rheum Dis. 2018; 77: 55-62.
DOI: https://doi.org/10.1136/annrheumdis-2017-211751
Clinicaltrials.gov. Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease (ATtackMy-ILD). Available from: https:// clinicaltrials.gov/ct2/show/NCT03215927. Accessed October 20, 2022.
LiS,LiW,JiangW,HeL,PengQ,WangG,et al. The efficacy of tocilizumab in the treatment of patients with refractory immune-mediated necrotizing myopathies: an open-label pilot study. Frontiers Pharmacol. 2021; 12: 635-54.
DOI: https://doi.org/10.3389/fphar.2021.635654
Sun S, Chen Z, Zhang D, Xu W, Wu W, Sun F, et al. Description and analysis of a novel subtype of the anti-synthetase syndrome characterized by frequent attacks of fever and systemic inflammation in a single-center cohort study. Frontiers Immunol. 2021; 12: 729602.
DOI: https://doi.org/10.3389/fimmu.2021.729602
Atienza-Mateo B, Remuzgo-Martínez S, Prieto-Peña D, Mora Cuesta VM, Iturbe-Fernández D, Llorca J, et al. Rituximab in the treatment of interstitial lung disease associated with autoimmune diseases: experience from a single referral center and literature review. J Clin Med. 2020; 9: 3070.
DOI: https://doi.org/10.3390/jcm9103070
Brulhart L, Waldburger JM, Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis. 2006; 65: 974-5.
DOI: https://doi.org/10.1136/ard.2005.045898
Vandenbroucke E, Grutters JC, Altenburg J, Boersma WG, ter Borg EJ, van den Bosch JM. Rituximab in life threatening antisynthetase syndrome. Rheumatol Int. 2009; 29: 1499-502.
DOI: https://doi.org/10.1007/s00296-009-0859-x
Limaye V, Hissaria P, Liew CL, Koszyka B. Efficacy of rituximab in refractory antisynthetase syndrome. Int Med J. 2012; 42: e4-e7.
DOI: https://doi.org/10.1111/j.1445-5994.2011.02702.x
Barsotti S, Cioffi E, Tripoli A, Tavoni A, d’Ascanio A, Mosca M, et al. The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature. Reumatismo. 2018; 70: 78-84.
DOI: https://doi.org/10.4081/reumatismo.2018.1011
Saunders P, Tsipouri V, Keir GJ, Ashby D, Flather MD, Parfrey H, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials. 2017; 18: 275.
DOI: https://doi.org/10.1186/s13063-017-2016-2
Thompson B, Corris P, Miller JA, Cooper RG, Halsey JP, Isaacs JD. Alemtuzumab (Campath-1H) for treatment of refractory polymyositis. J Rheumatol. 2008; 35: 2080-2.
ZouJ,LiT,HuangX,ChenS,GuoQ,BaoC. Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody. Ann Rheum Dis. 2014; 73: 1591-3.
DOI: https://doi.org/10.1136/annrheumdis-2014-205278
Furlan A, Botsios C, Ruffatti A, Todesco S, Punzi L. Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: a case report. Joint Bone Spine. 2008; 75: 366-7.
DOI: https://doi.org/10.1016/j.jbspin.2007.07.010
Zong M, Dorph C, Dastmalchi M, Alexanderson H, Pieper J, Amoudruz P, et al. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann Rheum Dis. 2014; 75: 913-20.
DOI: https://doi.org/10.1136/annrheumdis-2012-202857
Wendel S, Venhoff N, Frye BC, May AM, Agarwal P, Rizzi M, et al. Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib - a report of two cases. J Autoimmun. 2019; 100: 131-6.
DOI: https://doi.org/10.1016/j.jaut.2019.03.003
Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis–associated interstitial lung disease. N Engl J Med. 2019; 381: 291-3.
DOI: https://doi.org/10.1056/NEJMc1900045
Yu Z, Wang L, Quan M, Zhang T, Song H. Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: A pilot study and literature review. Rheumatology (Oxford). 2021; 60: 1700-7.
DOI: https://doi.org/10.1093/rheumatology/keaa558
Li S, SunY, Shao C, Huang H, Wang Q, Xu K, et al. Prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease: a retrospective study of 679 adult cases. Rheumatology (Oxford). 2021; 60: 1195-204.
DOI: https://doi.org/10.1093/rheumatology/keaa372
Fujisawa T, Hozumi H, Kono M, Enomoto N, Hashimoto D, Nakamura Y, et al. Prognostic factors for myositis-associated interstitial lung disease. PLoS One. 2014; 9: e98824.
DOI: https://doi.org/10.1371/journal.pone.0098824
Hervier B, Uzunhan Y. Inflammatory myopathy-related interstitial lung disease: from pathophysiology to treatment. Front Med (Lausanne). 2020; 6: 326.
DOI: https://doi.org/10.3389/fmed.2019.00326
YeS,ChenXX,LuXY,WuMF,DengY, Huang WQ, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol. 2007; 26: 1647-54.
DOI: https://doi.org/10.1007/s10067-007-0562-9
Gono T, Masui K, Nishina N, Kawaguchi Y, Kawakami A, Ikeda K, et al. Risk prediction modeling based on a combination of initial serum biomarker levels in polymyositis/dermatomyositis-associated interstitial lung disease. Arthritis Rheumatol. 2021; 73: 677-86.
DOI: https://doi.org/10.1002/art.41566
Cobo-Ibáñez T, López-Longo FJ, Joven B, Carreira PE, Muñoz-Fernández S, Maldonado-Romero V, et al. Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease. Clin Rheumatol. 2019; 38: 803-11.
DOI: https://doi.org/10.1007/s10067-018-4353-2
Supporting Agencies
This work was supported by Brazilian Society of RheumatologyHow to Cite
De Souza, F., De Araújo, D., Hoff, L., Baldi, B., Faria, M., da Rocha Junior, L., … Shinjo, S. (2023). Diagnosis and treatment of interstitial lung disease related to systemic autoimmune myopathies: a narrative review. Reumatismo, 75(1). https://doi.org/10.4081/reumatismo.2023.1571
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- S. Zingarelli, P. Airò, M. Frassi, C. Bazzani, M. Scarsi, M. Puoti, Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases , Reumatismo: Vol. 60 No. 1 (2008)
- P. Marson, G. Pasero, L. Punzi, G. Zanchin, On the main stages of the history of intra-articular therapy , Reumatismo: Vol. 59 No. 3 (2007)
- G. Leardini, M.T. Mascia, S. Stisi, G. Sandri, M. Franceschini, Sanitary costs of osteoarthritis , Reumatismo: Vol. 53 No. 4 (2001)
- T. Maio, P. Trezzi, M.A. Cimmino, Pure analgesics in a rheumatological outpatient clinic , Reumatismo: Vol. 53 No. 2 (2001)
- L. Cavagna, P. Rossi, L. Bogliolo, E. Antoniazzi, C. Gelmi, R. Caporali, C. Montecucco, Early electroretinografic changes in elderly RA patients treated with hydroxychloroquine , Reumatismo: Vol. 54 No. 3 (2002)
- A. Hoxha, A. Ruffatti, P. Grypiotis, M. Podswiadek, C. Botsios, U. Fiocco, L. Punzi, S. Todesco, Antinuclear, anti-dsDNA and anti-ENA antibodies in patients affected with rheumatoid arthritis or ankylosing spondylitis during treatement with infliximab , Reumatismo: Vol. 58 No. 2 (2006)
- A. Colangelo, F. Tromby, G. Cafaro, R. Gerli, E. Bartoloni, C. Perricone, Vasculitis associated with adenosine deaminase 2 deficiency: at the crossroads between Behçet’s disease and autoinflammation. A viewpoint , Reumatismo: Vol. 75 No. 3 (2023)
- A. Cossu, P.A. Cossu, A. Carcassi, Chronic polyarthritis in a patient affected by sarcoidosis and chronic HCV infection. Case report and review of the literature , Reumatismo: Vol. 54 No. 2 (2002)
- M. Rossini, F.P. Cantatore, A. Del Puente, B. Frediani, D. Gatti, S. Giannini, M. Varenna, O. Viapiana, G.D. Sebastiani, Expert opinion on the management of patients with osteoporosis with anabolic drugs in Italy , Reumatismo: Vol. 76 No. 2 (2024)
- G. Brambilla, A. Brucato, Y. Adler, M. Bosetti, P. Coppini, A. Caforio, D. Spodick, B. Canesi, Recurrent acute idiopathic pericarditis: rheumatologic therapy, autoantibodies and long term outcome , Reumatismo: Vol. 59 No. 1 (2007)
<< < 28 29 30 31 32 33 34 35 36 37 > >>
You may also start an advanced similarity search for this article.
